NeoChord Appoints Lori Adels, Ph.D. as Vice President of Clinical Affairs, Regulatory and Quality

EDEN PRAIRIE, Minn.--()--NeoChord, Inc., a medical technology company, announced today it has appointed Lori Adels, Ph.D. as Vice President of Clinical Affairs, Regulatory and Quality. In this role, Dr. Adels will lead the company’s efforts to design and execute a pivotal trial for U.S. Food and Drug Administration (FDA) approval of its disposable device for minimally invasive, percutaneous mitral valve repair. By expanding the reach of this technology, NeoChord will continue to enhance the level of care provided to patients with degenerative mitral valve regurgitation.

“Three decades of experience have enabled Lori to establish a strong reputation in the industry, commanding respect from her peers, the FDA and other stakeholders, and her achievements and expertise in the medical device field are unmatched,” said David Chung, President and Chief Executive Officer, NeoChord. “She will provide the regulatory and clinical direction we need to reach our strategic goals, drive transformation and truly change the way the medical field treats patients with degenerative mitral valve regurgitation.”

Most recently, Dr. Adels served as Executive Vice President of Regulatory and Clinical at Experien Group, where she was responsible for developing clients’ regulatory and clinical strategies; overseeing U.S. and international submissions; and providing regulatory support for product development, manufacturing and post-market compliance. She also served as the Vice President of Regulatory and Clinical Affairs of the Heart Valve Therapy Group at Edwards Lifesciences. In her professional experience, Dr. Adels has achieved premarket approval (PMA) from the FDA for more than ten submissions, the majority of which were in the heart valve space.

Dr. Adels’ deep experience also includes serving as a regulatory expert for numerous medical device companies, including Smart Therapeutics, APTUS, AtriCure and Sadra Medical. In addition, she has worked at Pfizer/Shiley, Baxter Healthcare EndoVascular Technologies (EVT) and Guidant Corporation where she led the regulatory efforts to achieve the first endovascular abdominal aortic aneurysm (AAA) device approval.

“The NeoChord technology crossed its 250th patient milestone in June and is currently being used to treat patients in ten European countries and Canada, so I am excited to be joining the company during such an important chapter of its growth,” said Dr. Adels. “I am committed to building on this momentum while ensuring NeoChord continues to surpass the market standard for treating patients with degenerative mitral valve regurgitation.”

About NeoChord, Inc.

Based in Eden Prairie, Minn., NeoChord, Inc. is a privately held medical technology company focused on advancing the treatment of mitral regurgitation. The Company received CE marking in Dec. 2012 for the DS1000 device for minimally invasive mitral valve repair via percutaneous implantation of artificial chordae tendinae. Mitral regurgitation is a progressive disease that can result in atrial fibrillation, congestive heart failure, and death when left untreated. For more information, visit: www.NeoChord.com.

Contacts

NeoChord Inc.
Beth Claseman, 952-698-7806
bclaseman@neochord.com

Release Summary

NeoChord, Inc., a medical technology company, announced today it has appointed Lori Adels, Ph.D. as Vice President of Clinical Affairs, Regulatory and Quality.

Contacts

NeoChord Inc.
Beth Claseman, 952-698-7806
bclaseman@neochord.com